Surge in prevalence of animal diseases led to the need of development of animal vaccines. Governments and market players have been taking various efforts to speed up development of vaccines that target different conditions among animals.
Animal Vaccines Industry:
Surge in prevalence of animal diseases led to the need of development of animal vaccines. Governments and market players have been taking various efforts to speed up development of vaccines that target different conditions among animals. Government authorities have been supporting private players in setting up laboratories and production facilities to accelerate the development of new vaccines. These vaccines target conditions such as Japanese encephalitis and others. The demand for different animal vaccines is expected to increase in the coming years. According to the report published by Allied Market Research, the global animal vaccines market is expected to reach $15.20 billion by 2030. Following are some of the activities taking place across the world.
Market players and governments have been realizing the importance of development of animal vaccines and setting up new facilities. Apiam Animal Health, one of the animal vaccine development firms in Australia, received a funding of $700,000 for development of laboratory from the Victorian Government’s Regional Jobs Fund. Through this funding, the company will build a laboratory in Bendigo. This facility is focused on development of vaccines to combat viruses such as Japanese encephalitis virus (JEV) from pig population in the country. Moreover, this laboratory will scale up the production of JEV to fulfill the existing gap in the industry.
The firm has been collaborating with researchers from the La Trobe University. These researchers have been working on development of innovative technology for safe and rapid production of vaccines. The new lab will enable Apiam raise export activities of animal vaccines in the international market. This laboratory is estimated to be completed by the end of 2025. Moreover, it will fulfill the highest biosecurity standards along with boasting a number of self-contained modular laboratories.
The development of new facilities for development of animal vaccines continues. Pacific GeneTech plans the manufacturing facility of animal vaccines that target pathogens such as Eimeria, Salmonella, and Avian influenza. Arkansas Agricultural Experiment Station licensed the facility. The new facility will have a vaccine development laboratory and the U.S. headquarters of the company. The innovative vaccine technology developed by Pacific provides several benefits over traditional vaccines. These vaccines are long-lasting and do not leave any tissue lesions such as oil emulsion adjuvants. Moreover, they can be administered as an inactivated vaccine through oral means. The vaccines developed in the facility will be used in poultry animals. The facility is expected to be operational by the first quarter of 2023.
Request for Sample Report for More Insights @ https://www.alliedmarketresearch.com/request-sample/1988
Top Leading Players:
Key players operating in the animal vaccines industry. These players include Merck & Co., Inc., Zoetis Inc., Ceva Santé Animale, Sanofi S.A., Romvac, Vaxxinova, Biovac, Merial, Boehringer Ingelheim GmbH and Anicon Labor GmbH. The other players that operate in animal vaccines market include Nexvet, PHL Associates, Inc., Hygieia Biological Laboratories, Colorado Serum Company, Pfizer, and Arko Laboratories, Ltd.
Covid-19 Scenario-
Here, it’s worth mentioning that the outbreak of the Covid-19 pandemic gave way to adjournment of the majority of elective surgeries across the world, which in turn resulted into a steep decline in demand for Animal Vaccines, thereby impacting the market negatively, especially during the initial period. However, as the global situation is getting back to normalcy, the market is also projected to revive soon.